
CLAIMS

What is claimed is:

1. A compound of Formula I:




(I)

or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group.

2. The compound of claim 1 wherein R is $R_1C(O)$-, wherein R_1 is substituted or unsubstituted C_1-C_{24}-alkyl; substituted or unsubstituted C_2-C_{24}-alkenyl, preferably C_2-C_{10}-alkenyl, and more preferably C_2-C_6-alkenyl; substituted or unsubstituted C_2-C_{24}-alkynyl; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl.

3. The compound of claim 1 wherein R is H or acetyl.

4. The compound of claim 1 represented by the formula:



,

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising as an active ingredient a compound of claim 1 and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition for oral administration comprising as an active ingredient a compound of claim 1 and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising as an active ingredient a compound of claim 4 and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition for oral administration comprising as an active ingredient a compound of claim 4 and a pharmaceutically acceptable carrier.

9. A method of treating a PI3K related disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 5.

10. The method of claim 9, wherein said PI3K related disease or disorder is a cell proliferative disorder.

11. The method of claim 10 wherein the cell proliferative disorder is a cancer.

12. The method of claim 11, wherein the cancer is selected from the group consisting of papilloma, blastoglioma, Kaposi's sarcoma, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, leukemia, lymphoma, Hodgkin's disease and Burkitt's disease.

13. A method of treating an HDAC-mediated disease comprising administering to a subject in need thereof a pharmaceutical composition of claim 5.

14. A method of treating both PI3K and HDAC mediated diseases comprising administering to a subject in need thereof a pharmaceutical composition of claim 5.

15. A method of treating a PI3K related disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 7.

16. The method of claim 13 wherein said PI3K related disease or disorder is a cell proliferative disorder.

17. The method of claim 16 wherein the cell proliferative disorder is a cancer.

18. The method of claim 17 wherein the cancer is selected from the group consisting of papilloma, blastoglioma, Kaposi's sarcoma, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, leukemia, lymphoma, Hodgkin's disease and Burkitt's disease.


19. A method of treating an HDAC-mediated disease comprising administering to a subject in need thereof a pharmaceutical composition of claim 7.

20. A method of treating both PI3K and HDAC mediated diseases comprising administering to a subject in need thereof a pharmaceutical composition of claim 7.

CLAIMS

What is claimed is:

1. A compound of Formula I:




(I)

or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group.

2. The compound of claim 1 wherein R is $R_1C(O)$-, wherein R_1 is substituted or unsubstituted C_1-C_{24}-alkyl; substituted or unsubstituted C_2-C_{24}-alkenyl; substituted or unsubstituted C_2-C_{24}-alkynyl; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl.

3. The compound of claim 1 wherein R is H or acetyl.

4. The compound of claim 1 represented by the formula:



,

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising as an active ingredient a compound of claim 1 and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition for oral administration comprising as an active ingredient a compound of claim 1 and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising as an active ingredient a compound of claim 4 and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition for oral administration comprising as an active ingredient a compound of claim 4 and a pharmaceutically acceptable carrier.

9. A method of treating a PI3K related disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 5.

10. The method of claim 9, wherein said PI3K related disease or disorder is a cell proliferative disorder.

11. The method of claim 10 wherein the cell proliferative disorder is a cancer.

12. The method of claim 11, wherein the cell proliferative disorder is selected from the group consisting of papilloma, glioblastoma, Kaposi's sarcoma, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, leukemia, lymphoma, Hodgkin's disease and Burkitt's disease.

13. A method of treating an HDAC-mediated disease comprising administering to a subject in need thereof a pharmaceutical composition of claim 5.

14. A method of treating a disease mediated by both PI3K and HDAC comprising administering to a subject in need thereof a pharmaceutical composition of claim 5.

15. A method of treating a PI3K related disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 7.

16. The method of claim 15 wherein said PI3K related disease or disorder is a cell proliferative disorder.

17. The method of claim 16 wherein the cell proliferative disorder is a cancer.

18. The method of claim 16 wherein the cell proliferative disorder is selected from the group consisting of papilloma, glioblastoma, Kaposi's sarcoma, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, leukemia, lymphoma, Hodgkin's disease and Burkitt's disease.

19. A method of treating an HDAC-mediated disease comprising administering to a subject in need thereof a pharmaceutical composition of claim 7.

20. A method of treating a disease mediated by both PI3K and HDAC comprising administering to a subject in need thereof a pharmaceutical composition of claim 7.